In-vivo Models and Studies
LIDE’s foundation is built on in vivo oncology studies, providing researchers with robust, translational platforms that span from traditional CDX models to cutting-edge innovations like MiniPDX® and IO-FIVE™. With one of the world’s largest biobanks and continuous technology development, LIDE enables drug developers to move faster, reduce risk, and increase confidence in clinical translation.
2300+ Patient Derived Xenograft (PDX) Models
PDX models are still the gold standard for IND-enabling efficacy studies. LIDE’s industry leading PDX library offers our clients access to unique, patient-consented, highly characterized, low-passage tumors:
· 50 oncology indications covered
· 370+ naturally derived resistant models
· World’s largest biobank of pretreated models
· Variant rich: rare mutations and high-profile targets
Learn More ›
MiniPDX®: the 7 Day In Vivo 3D Organoid
Our proprietary MiniPDX and IO-FIVE tests provide fast and actionable in-vivo feedback for your go or no-go development decisions.
· Results in 7-10 days
· Supports wider range of drugs and dosing protocols than in-vitro methods
· More cost effective than traditional PDX
· 92% correlated with PDX results
· Optimized over 10 years in 3000+ studies; validated by multiple publications
Learn More ›
Cell Line Derived Xenograft (CDX) Models
CDX models are a well established and a widely used for early in-vivo screening. LIDE has a growing bank ready for client application.
· 120 models ready to use. 46 with SOC data.
· New models established at minimal client cost
· Cost effective and fast turnaround time
Learn More ›
Orthotopic Models
We offer orthotopic models built on PDX and CDX tissue, and across a wide spectrum of solid and liquid cancers.
· Wide spectrum of cancer types and hematological tumors
· Available from PDX or CDX cells
· Luciferase-labeled tumor cells for non-invasive monitoring
Learn More ›
Syngeneic Mouse Models
LIDE offers fully immunocompetent murine tumor models for rapid proof-of-concept and mechanism-of-action studies.
· Diverse collection across solid, blood, and orthotopic models
· Available with or without bioluminescent variants for real-time, non-invasive tumor monitoring
· Cost effective and fast turnaround time
Learn More ›
Humanized Models
More advanced IO drug development demands models that accurately reflect the human immune system’s interaction with tumors.
· Multiple formats available – HuPBMC, HuHSC, and humanized syngeneic knock-in mice
· Compatible with checkpoint inhibitors, bispecifics, oncolytic viruses
· Unique co-inoculation platform overcomes GvHD issues seen in classical reconstituted models
Learn More ›